CCL2 and metabolic dysfunction-associated steatohepatitis: mNOX-E36, a CCL2 inhibitor, can suppress the recruitment of MoMFs to the liver in CCl4-induced liver fibrosis models and methionine–choline-deficient diet (MCD)-induced NASH model.